SSI Mantra, the first made-in-India surgical robotic system, has completed the country’s inaugural human trial in telesurgery. SS Innovations, the developers of the system, announced this achievement, highlighting a significant advancement in surgical robotics. The latest version, SSI Mantra 3, was pivotal in this accomplishment. The trial involved a robotic cholecystectomy performed between the World Laparoscopy Hospital and the SSI Headquarters, covering a distance of 5 kilometers.
This successful trial demonstrates the potential of the SSI Mantra 3 in enabling remote surgeries, which can revolutionize the accessibility and precision of surgical procedures. Dr. Sudhir Srivastava, Founder, Chairman, and CEO of SS Innovations, expressed pride in contributing to the Make in India initiative with this development. He emphasized the commitment to advancing innovation and accessibility in robotic surgeries with the launch of SSI Mantra 3 and the completion of India’s first human trial in soft tissue telesurgery.
The SSI Mantra 3 is an advanced system designed to enhance surgical precision, efficiency, and patient outcomes. It features five slender robotic arms and an immersive 3D HD headset, providing surgeons with exceptional optics and a vision cart that offers 3D 4K vision to the entire team. This ensures unparalleled precision and control during surgeries. The company also stressed the cost-effective pricing of the SSI Mantra 3, aiming to make advanced surgical technologies more accessible to healthcare institutions in India and globally.
As reported by International Business Times, SSI Mantra 3 enables smaller fingertip-sized incisions, resulting in less pain, minimal blood loss, reduced scarring, faster recovery, and shorter hospital stays. Its cost-effectiveness will make advanced robotic surgery more accessible to hospitals, doctors, and patients, ensuring precision and efficiency across various specialties, including robotic cardiac surgery.